Abstract:In solid malignancies, T cells functionality is intertwined with metabolic reprogramming within the tumor microenvironment (TME), which supports the increased energy request of cancer cells and suppresses the effector function and cytokines production of the immune infiltrate. In primary colorectal cancer (CRCs) and related liver metastases, we revealed extensive transcriptional remodeling across tumors, being metabolic pathways among the major drivers of this variance. Accordingly, extracellular adenosine, accumulating in the TME for the hydrolysis of ATP by CD39 and CD73, has been recognized as a novel inhibitory mediator, which binds preferentially to the A2A receptor (A2Ar) to exert its immunosuppressive activity. By high dimensional flow cytometry, we revealed that CD39 is a major driver of T-cell exhaustion in primary and metastatic CRCs. Therefore, we sought to disrupt CD39 in TCR-edited T cells (TCRED). By CRISPR/Cas9, we disrupted both the α and β chains of the endogenous TCR together with ENTPD1, the gene encoding for CD39, and redirected T cell specificity against the HER2 antigen. TCREDCD39KO T cells outperformed their competent counterpart in eliminating patient-derived organoids (PDOs) from primary and metastatic tumors both in vitro and in vivo. Given the role of CD39 in starting the biochemical cascade leading to adenosine production, we aimed at investigating the direct role of adenosine on the functional advantage observed with TCREDCD39KO T cells. We challenged our cellular products with target cells in the presence or absence of adenosine and observed that TCREDCD39KO T cells are superior to their competent counterpart in the ability to release cytokines, while the effect is completely abolished when adenosine is present. Also, when TCREDCD39KO T cells were challenged with PDOs, the exogenously added adenosine nullifies the functional killing advantage given by the CD39 KO. To gain more insights into the pathway, we also generated TCREDA2ArKO T cells. In line with the different roles of CD39 and A2AR on the ATP/adenosine pathway, the disruption of the adenosine receptor resulted in a significant advantage in PDO killing in the presence of adenosine only. We then evaluated the influence of CD39KO in the metabolic capacity of T cells and revealed that TCREDCD39KO T cells have a greater potential to rely on the mitochondrial other than glycolytic functions, which explains higher functionality and persistence. Further evaluation on the metabolic effect of CD39 KO are currently ongoing. Overall, we showed that the ATP/adenosine cascade is relevant for T cells functionality and metabolic status and can be harnessed in adoptive cell therapy strategies to counteract the immunosuppressive TME. Citation Format: Alessia Potenza, Chiara Balestrieri, Martina Spiga, Luca Albarello, Federica Pedica, Arianna Ferrari, Oronza A. Botrugno, Barbara Camisa, Elena Tiziano, Camilla Sirini, Monica Casucci, Chiara Iozzi, Danilo Abbati, Ugo Elmore, Giulia Di Lullo, Giulia Casorati, Claudio Doglioni, Giovanni Tonon, Paolo Dellabona, Riccardo Rosati, Luca Aldrighetti, Paolo Monti, Eliana Ruggiero, Chiara Bonini. Metabolic reprogramming of the tumor microenvironment to enhance the functionality of TCR-edited T cell in colorectal cancer and liver metastases [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3596.

Extracellular adenosine oppositely regulates the purinome machinery in glioblastoma and mesenchymal stem cells

Inhibiting Adenine Synthesis Attenuates Glioblastoma Cell Stemness and Temozolomide Resistance

The Impact of A3AR Antagonism on the Differential Expression of Chemoresistance-Related Genes in Glioblastoma Stem-like Cells

Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.

Abstract 734: Inhibition of equilibrative nucleoside transporter 1 relieves intracellular adenosine-mediated immune suppression

Extracellular adenosine metabolism in immune cells in melanoma

Adenosine increases PD‐L1 expression in mesenchymal stromal cells derived from cervical cancer through its interaction with A2AR/A2BR and the production of TGF‐β1

Tmic-49. Tumor-Derived Spermidine Drives Immune Suppression In The Glioblastoma Microenvironment Via Cd8 T Cell Depletion And Functional Attenuation

Integrating bulk-RNA sequencing and single-cell sequencing analyses to characterize adenosine-enriched tumor microenvironment landscape and develop an adenosine-related prognostic signature predicting immunotherapy in lung adenocarcinoma

Purine Synthesis Inhibitor L-Alanosine Impairs Mitochondrial Function and Stemness of Brain Tumor Initiating Cells

Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors

Abstract 3596: Metabolic reprogramming of the tumor microenvironment to enhance the functionality of TCR-edited T cell in colorectal cancer and liver metastases

Antitumoral Activity of the Universal Methyl Donor S-Adenosylmethionine in Glioblastoma Cells

The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies

Glioma Stem Cells Upregulate CD39 Expression to Escape Immune Response through SOX2 Modulation

Adipose-derived stromal cell secretome disrupts autophagy in glioblastoma

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function

Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression

Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer

ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment

ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain